Rheumatoid arthritis (RA) and osteoarthritis (OA) cause enormous patient suff ering and economic burden. Due to non-steroidal anti-infl ammatory drug (NSAID)-and cyclooxygenase-2 (COX-2) inhibitor-associated ulcers and cardiovascular adverse events, novel anti-arthritis therapies are needed. Natural health product (NHP) use by patients to alleviate symptoms is rising globally. However, the quality of NHPs is poorly regulated and their effi cacy, toxicity and mechanism(s) of action are not understood. Using state-of-the-art approaches, Haqqi and colleagues report in Arthritis Research and Th erapy [1] that human chondrocytes expressed the p38-mitogenactivated protein kinase (MAPK) isoforms p38α, -γ and -δ, but not p38β. IL-1β enhanced phosphorylation of p38α-MAPK and p38γ-MAPK but not of p38δ-MAPK. Th ey showed by gene-silencing that p38-MAPK activation was mediated by mitogen-activated protein kinase kinase 3 (MKK3). A standardized pomegranate extract (PE) specifi cally diminished IL-1-induced and MKK3-activated p38α-MAPK isoform and Runx2 (runt-related transcription factor 2) activity. PE did not interfere with the binding of IL-1β to IL-1 receptor, thus ruling out steric hindrance as a suppression mechanism. PE also inhibited JNK-MAPK and NF-κB activity.
Considering the non-toxicity of PE in chondrocytes and its eff ectiveness in RA and OA models, identifying precise pomegranate active ingredients, their synergistic eff ects and utility for preventing or reducing human OA and RA through clinical trials is warranted. Epidemiological studies on non-consuming and pomegranateconsum ing populations for incidence of arthritis may also be useful. One should also analyze potential pharmaco logical drug-PE interactions.
Th e anti-arthritic eff ects of green tea are attributed to the multiple activities of non-toxic epigallocatechin-3-gallate (EGCG). It suppresses IL-1-induced glycosaminoglycan release from cartilage by inhibiting ADAMTS, MMP-1 and MMP-13 expression through preferentially blocking NF-κB activity in chondrocytes. EGCG also inhibits IL-1-stimulated inducible nitric oxide synthase (iNOS), nitric oxide and JNK activities, which mediate cartilage degradation. In RA synovial fi broblasts, EGCG inhibits TNF-α-induced MMP-1, MMP-3, ERK (extracellular signal-regulated kinase), p38, JNK and AP-1 activities. EGCG sensitizes RA fi broblasts to TNF-α-induced caspase-3-mediated apoptosis by blocking Akt and NF-κB cell survival pathways. EGCG also inhibits IL-6 receptor-induced MMP-2, increases gp130 receptor in fi broblasts and ameliorates adjuvant-induced rat arthritis. EGCG suppresses osteoclast-specifi c, NF-ATc1 and RA-associated bone resorption and ameliorates mouse arthritis. It inhibited oncostatin M-stimulated CCL2 chemokine expression in human osteoblasts and reduced severity of collagen-induced arthritis. Th ese in vitro and in vivo studies suggest that EGCG could reduce synovial hyperplasia, cartilage degradation and bone resorption by modulating multiple targets in joints [9] . Despite its apparent safety in clinical trials of other diseases, its potential for causing apoptosis in chondrocytes should be tested further.
Resveratrol from grapes displays anti-infl ammatory and chondroprotective activities by increasing proteoglycan synthesis and chondrocyte proliferation and by suppressing IL-1, reactive oxygen species, p53-induced apoptosis, leukotriene B4, prostaglandin E2 synthesis and MMPs in vitro [10] . Intra-articular resveratrol treatment reduced cartilage loss in rabbit arthritis models. Resveratrol induced fi broblast apoptosis but increased chondrocyte survival by activating Sirtuin 1 (a histone deacetylase) and Bcl2 [11, 12] . Th us, resveratrol may prevent intervertebral disc degeneration, OA-associated infl ammation, chondrocyte apoptosis, and RA-related pannus formation, desirable goals in treating OA and RA. Resveratrol-like Sirtuin 1 activators are also being developed as lifespan-extending drugs.
Curcumin suppresses infl ammatory and catabolic mediators such as IL-1β-stimulated nitric oxide, prostaglandin E2, COX-2, IL-6, IL-8, MMP-3, MMP-9, JNK and NF-κB activation and the oncostatin M-induced JAK/ STAT pathway in human chondrocytes [13] . It promotes chondrogenesis from mesenchymal stem cells by antagonizing proinfl ammatory cytokines [14] . Despite these anti-infl ammatory, antioxidant, anti-angiogenic activities, its oral consumption and tissue bioavailability are problem atic. Other NHPs, quercetin, triptolide and silymarin, target infl ammatory cytokines, NF-κB, COX-2 and catabolic MMPs [15] .
It is laudable that regulatory agencies are encouraging research to substantiate the therapeutic claims by manufacturers of NHPs. We need well-controlled, molecular and mechanistic studies on NHPs as modeled by Haqqi and colleagues [1] . Currently, we can analyze multiple targets of NHPs by gene arrays and proteomics to evaluate their effi cacy in preventing and treating RA and OA.
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